Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models.

Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ.

Mol Cancer Ther. 2019 Oct 9. pii: molcanther.0414.2019. doi: 10.1158/1535-7163.MCT-19-0414. [Epub ahead of print]

PMID:
31597714
2.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity.

Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaax0720. doi: 10.1126/scitranslmed.aax0720.

PMID:
31578241
3.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.

Huang ZR, Tipparaju SK, Kirpotin DB, Pien C, Kornaga T, Noble CO, Koshkaryev A, Tran J, Kamoun WS, Drummond DC.

J Control Release. 2019 Sep 28;310:47-57. doi: 10.1016/j.jconrel.2019.08.006. Epub 2019 Aug 7.

PMID:
31400383
4.

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials".

de Vlieger JSB, Crommelin DJA, Tyner K, Drummond DC, Jiang W, McNeil SE, Neervannan S, Crist RM, Shah VP.

AAPS J. 2019 Apr 17;21(4):56. doi: 10.1208/s12248-019-0329-7.

5.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.

PMID:
30952988
6.

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC.

Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14.

PMID:
30654182
7.

Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics.

Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA, Raue A.

Cell Rep. 2018 Nov 6;25(6):1458-1468.e4. doi: 10.1016/j.celrep.2018.10.047.

8.

Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway.

Alkan O, Schoeberl B, Shah M, Koshkaryev A, Heinemann T, Drummond DC, Yaffe MB, Raue A.

Sci Signal. 2018 Jul 24;11(540). pii: eaat0229. doi: 10.1126/scisignal.aat0229.

PMID:
30042127
9.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

10.

Discovery of internalizing antibodies to basal breast cancer cells.

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD.

Protein Eng Des Sel. 2018 Jan 1;31(1):17-28. doi: 10.1093/protein/gzx063.

11.

New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.

Louis N, Liu S, He X, Drummond DC, Noble CO, Goldman S, Mueller S, Bankiewicz K, Gupta N, Hashizume R.

J Neurooncol. 2018 Feb;136(3):475-484. doi: 10.1007/s11060-017-2681-8. Epub 2017 Nov 23.

12.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.

Leonard SC, Lee H, Gaddy DF, Klinz SG, Paz N, Kalra AV, Drummond DC, Chan DC, Bunn PA, Fitzgerald JB, Hendriks BS.

Anticancer Drugs. 2017 Nov;28(10):1086-1096. doi: 10.1097/CAD.0000000000000545.

PMID:
28857767
13.

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.

Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD.

Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23.

PMID:
28233053
14.

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.

Ramanathan RK, Korn RL, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB.

Clin Cancer Res. 2017 Jul 15;23(14):3638-3648. doi: 10.1158/1078-0432.CCR-16-1990. Epub 2017 Feb 3.

15.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.

Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA.

MAbs. 2017 Jan;9(1):58-67. doi: 10.1080/19420862.2016.1259047. Epub 2016 Nov 17.

16.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.

Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP.

Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.

17.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.

Zhang K, Geddie ML, Kohli N, Kornaga T, Kirpotin DB, Jiao Y, Rennard R, Drummond DC, Nielsen UB, Xu L, Lugovskoy AA.

MAbs. 2015;7(1):42-52. doi: 10.4161/19420862.2014.985933.

18.

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB.

Cancer Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.CAN-14-0572. Epub 2014 Oct 1.

19.

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.

Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, Hadaczek P, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW.

Nanomedicine (Lond). 2014 Jul;9(14):2099-108. doi: 10.2217/nnm.13.201. Epub 2014 Feb 4.

PMID:
24494810
20.

Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.

Weng KC, Hashizume R, Noble CO, Serwer LP, Drummond DC, Kirpotin DB, Kuwabara AM, Chao LX, Chen FF, James CD, Park JW.

Nanomedicine (Lond). 2013 Dec;8(12):1913-25. doi: 10.2217/nnm.12.209. Epub 2013 Apr 30.

PMID:
23631502
21.

Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD.

Neuro Oncol. 2013 Feb;15(2):189-97. doi: 10.1093/neuonc/nos305. Epub 2012 Dec 21.

22.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, L├╝cker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.

PMID:
22676972
23.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC.

Methods Enzymol. 2012;502:139-66. doi: 10.1016/B978-0-12-416039-2.00007-0.

PMID:
22208985
24.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD.

Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27.

25.

Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, Yamashita Y, Krauze MT, Forsayeth J, Noble CO, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS.

Neuro Oncol. 2010 Sep;12(9):928-40. doi: 10.1093/neuonc/noq046. Epub 2010 May 20.

26.

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB.

J Control Release. 2010 Jan 4;141(1):13-21. doi: 10.1016/j.jconrel.2009.08.006. Epub 2009 Aug 15.

PMID:
19686789
27.

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC.

Cancer Chemother Pharmacol. 2009 Sep;64(4):741-51. doi: 10.1007/s00280-008-0923-3. Epub 2009 Jan 30.

28.

Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.

Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, Tseng YL, Hong K, Kirpotin DB.

J Pharmacol Exp Ther. 2009 Jan;328(1):321-30. doi: 10.1124/jpet.108.141200. Epub 2008 Oct 23.

29.

Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

Weng KC, Noble CO, Papahadjopoulos-Sternberg B, Chen FF, Drummond DC, Kirpotin DB, Wang D, Hom YK, Hann B, Park JW.

Nano Lett. 2008 Sep;8(9):2851-7. doi: 10.1021/nl801488u. Epub 2008 Aug 20.

PMID:
18712930
30.

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB.

J Pharm Sci. 2008 Nov;97(11):4696-740. doi: 10.1002/jps.21358. Review.

PMID:
18351638
31.

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

An F, Drummond DC, Wilson S, Kirpotin DB, Nishimura SL, Broaddus VC, Liu B.

Mol Cancer Ther. 2008 Mar;7(3):569-78. doi: 10.1158/1535-7163.MCT-07-2132. Epub 2008 Mar 4.

32.

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B.

Mol Cancer Ther. 2007 Oct;6(10):2737-46.

33.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD.

J Mol Biol. 2007 Aug 24;371(4):934-47. Epub 2007 May 10.

34.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD.

J Mol Med (Berl). 2007 Oct;85(10):1113-23. Epub 2007 Jun 7.

PMID:
17554518
35.

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA.

Mol Immunol. 2007 Jul;44(15):3777-88. Epub 2007 May 10.

36.

Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N 4th, Park JW, Marks JD, Benz CC, Kirpotin DB.

Mol Pharm. 2006 Nov-Dec;3(6):726-36.

PMID:
17140260
37.
38.

A novel assay for monitoring internalization of nanocarrier coupled antibodies.

Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD.

BMC Immunol. 2006 Oct 2;7:24.

39.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.

Cancer Res. 2006 Jul 1;66(13):6732-40.

40.

Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS.

Neuro Oncol. 2006 Jul;8(3):205-14. Epub 2006 May 24.

41.

Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.

Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB.

Biochim Biophys Acta. 2006 Apr;1758(4):429-42. Epub 2006 Apr 17.

42.

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB.

Cancer Res. 2006 Mar 15;66(6):3271-7.

43.

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DB, Bankiewicz KS, Park JW.

Cancer Res. 2006 Mar 1;66(5):2801-6.

44.

Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.

Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW, Bankiewicz KS.

J Neurosci Methods. 2006 Jun 30;154(1-2):225-32. Epub 2006 Feb 10.

PMID:
16472868
45.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW.

Cancer Res. 2005 Dec 15;65(24):11631-8.

46.

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K.

Gene Ther. 2006 Apr;13(7):646-51.

PMID:
16341056
47.

Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.

Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS.

Exp Neurol. 2005 Dec;196(2):381-9. Epub 2005 Sep 28.

PMID:
16197944
48.

Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.

Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB.

Biotechnol Prog. 2005 Jan-Feb;21(1):221-32.

PMID:
15903261
49.

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL.

Biotechnol Prog. 2005 Jan-Feb;21(1):205-20.

PMID:
15903260
50.

Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC.

Clin Cancer Res. 2005 May 1;11(9):3392-401.

Supplemental Content

Loading ...
Support Center